Aura Biosciences (AURA) Expected to Announce Quarterly Earnings on Tuesday

Aura Biosciences (NASDAQ:AURA) is projected to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Aura Biosciences to post earnings of ($0.46) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 9:30 AM ET.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aura Biosciences Trading Down 1.1%

Shares of NASDAQ:AURA opened at $5.35 on Monday. The stock has a market cap of $332.34 million, a PE ratio of -2.73 and a beta of 0.45. The stock’s fifty day simple moving average is $6.09 and its two-hundred day simple moving average is $6.23. Aura Biosciences has a 1-year low of $4.34 and a 1-year high of $11.22.

Insider Activity at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 9,049 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $6.35, for a total transaction of $57,461.15. Following the completion of the transaction, the insider owned 474,391 shares in the company, valued at approximately $3,012,382.85. This represents a 1.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Mark Plavsic sold 12,169 shares of Aura Biosciences stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $6.35, for a total value of $77,273.15. Following the completion of the sale, the chief technology officer directly owned 197,287 shares of the company’s stock, valued at approximately $1,252,772.45. This trade represents a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 29,836 shares of company stock worth $192,161. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Aura Biosciences by 16.7% in the third quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company’s stock valued at $17,863,000 after purchasing an additional 413,001 shares during the period. Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 67.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock valued at $13,257,000 after acquiring an additional 850,000 shares during the period. Ameriprise Financial Inc. raised its holdings in Aura Biosciences by 31.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 84,558 shares of the company’s stock valued at $529,000 after acquiring an additional 20,065 shares during the period. Gallagher Fiduciary Advisors LLC purchased a new stake in shares of Aura Biosciences during the second quarter worth $189,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Aura Biosciences by 12.3% in the third quarter. JPMorgan Chase & Co. now owns 24,557 shares of the company’s stock worth $152,000 after acquiring an additional 2,693 shares during the period. Institutional investors own 96.75% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on AURA. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Wednesday. Zacks Research upgraded shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Aura Biosciences currently has an average rating of “Moderate Buy” and an average target price of $20.50.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.